NeuroSense Therapeutics
value proposition | NeuroSense Therapeutics
Company
Deck Type
Sector
Industry
Deck date
June 2023
Slide
5 of 34
Similar slides by NeuroSense Therapeutics
See diffirences between slides (animation)
Investor Presentation
June 2023
highlights summary | NeuroSense Therapeutics
Related slides by other companies
Ocuphire Pharma
Results
June 2021
topline phase results randomized center double masked placebo controlled study of the safety and efficacy of ophthalmic solution low dose pilocarpine for the treatment of presbyopia | Ocuphire Pharma
Dare Bioscience
Investor Presentation
February 2023
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
Other recent decks by NeuroSense Therapeutics
See all presentations (4 decks)
Investor Presentation
October 2024
Investor Presentation
January 2024
Investor Presentation
December 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights